ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case-Control Study.
Open access · bronzeAbstract readMulticenter Study
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Liquid-based kidney injury molecule-1 as a diagnostic and prognostic indicator in renal cell carcinoma: A systematic review and meta-analysis.International urology and nephrology · 2025Pooled it
- Risk Prediction Models for Kidney Cancer: A Systematic Review.European urology focus · 2021Pooled it
- Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805).Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC.Nature reviews. Clinical oncology · 2026Article
- 1H MR-based detection of human plasma metabolic alterations in clear cell renal cell carcinoma.BJUI compass · 2026Article
- KIM-1 as a Biomarker in Genitourinary Neoplasms.Cancers · 2026Review
- Towards Precision Medicine in Metastatic Renal Cell Carcinoma: The Role of Emerging Biomarkers.Cancers · 2026Review
- Pre-diagnostic plasma proteomics profile uncovers new biomarkers and mechanistic insights for incident kidney cancer.International journal of surgery (London, England) · 2026Article
- Association of KIM-1 (HAVCR1) Expression with the Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma.Current gene therapy · 2026Article
- Atrazine use and markers of kidney function and nephrotoxicity among male farmers in the Biomarkers of Exposure and Effect in Agriculture Study.Occupational and environmental medicine · 2025Article
- Emerging technologies and clinical translation of urine-based liquid biopsy in urological cancers.Genes & genomics · 2025Review
- Blood Biomarkers to Identify Renal Angiomyolipomas in People With Tuberous Sclerosis Complex.Neurology. Genetics · 2025Article
- Kidney Injury Molecule-1 Expression in Pathological T1b Clear Cell Renal Cell Carcinoma: A Putative Biomarker of High Immune-Inflamed Status and Recurrence.Pathology international · 2025Article
- Current and novel biomarkers in cardiogenic shock.European journal of heart failure · 2025Review
- KIM-1 as a Prognostic Marker in Renal Cell Carcinoma.European urology focus · 2025Article
- Identification and validation of glycosyltransferase-related gene signatures to predict prognosis and immunological characteristics of renal clear cell carcinoma.Translational andrology and urology · 2025Article
- Kidney Injury Molecule-1 as a Biomarker for Renal Cancer: Current Insights and Future Perspectives-A Narrative Review.International journal of molecular sciences · 2025Review
- Biomarker-informed care for patients with renal cell carcinoma.Nature cancer · 2025Review
- Tumor-initiating and metastasis-initiating cells of clear-cell renal cell carcinoma.Journal of biomedical science · 2025Review
- From acute tubular injury to tubular repair and chronic kidney diseases - KIM-1 as a promising biomarker for predicting renal tubular pathology.Current research in physiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 20 institutions in 13 countries.
Ghislaine Scelo *International Agency for Research on Cancer (IARC), Lyon, France.
David C Muller *Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom. david.muller@imperial.ac.uk rbhatt@bidmc.harvard.edu.
Elio RiboliDepartment of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom.
Mattias JohanssonInternational Agency for Research on Cancer (IARC), Lyon, France.
Amanda J CrossDepartment of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom.ORCID 0000-0002-0893-2377
Paolo VineisDepartment of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom.
Konstantinos K TsilidisDepartment of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom.ORCID 0000-0002-8452-8472
Paul BrennanInternational Agency for Research on Cancer (IARC), Lyon, France.
Heiner BoeingDepartment of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Petra H M PeetersJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands.
Roel C H VermeulenInstitute for Risk Assessment Sciences, Utrecht University, the Netherlands.
Kim OvervadDepartment of Public Health, Section for Epidemiology, Aarhus University, Denmark.
H Bas Bueno-de-MesquitaDepartment of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom.
Gianluca SeveriCESP, Faculté de Médecine, Université Paris-Sud, Faculté de médecine, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.ORCID 0000-0001-7157-419X
Vittorio PerducaCESP, Faculté de Médecine, Université Paris-Sud, Faculté de médecine, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.ORCID 0000-0003-0339-0473
Marina KvaskoffCESP, Faculté de Médecine, Université Paris-Sud, Faculté de médecine, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
Antonia TrichopoulouHellenic Health Foundation, Athens, Greece.
Carlo La VecchiaHellenic Health Foundation, Athens, Greece.
Anna KarakatsaniHellenic Health Foundation, Athens, Greece.ORCID 0000-0002-3275-2026
Domenico PalliCancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute, ISPO, Florence, Italy.ORCID 0000-0002-5558-2437
Sabina SieriEpidemiology and Prevention Unit Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Salvatore PanicoDipartimento Di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
Elisabete WeiderpassDepartment of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.ORCID 0000-0003-2237-0128
Torkjel M SandangerDepartment of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Therese H NøstDepartment of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Antonio AgudoUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Institut Catatlà d'Oncologia, L'Hospitalet de Llobregat, Spain.
J Ramón QuirósPublic Health Directorate, Asturias, Spain.
Miguel Rodríguez-BarrancoEscuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.ORCID 0000-0002-9972-9779
Maria-Dolores ChirlaqueCIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Timothy J KeyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford.
Prateek KhannaDepartment of Medicine, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Joseph V BonventreBrigham and Women's Hospital, Harvard Institutes of Medicine, Boston, Massachusetts.
Venkata S SabbisettiBrigham and Women's Hospital, Harvard Institutes of Medicine, Boston, Massachusetts.
Rupal S BhattDepartment of Medicine, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts. david.muller@imperial.ac.uk rbhatt@bidmc.harvard.edu.
Imperial College London · GBCentre international de recherche sur le cancer · FRUniversité Paris-Sud · FRBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USUiT The Arctic University of Norway · NOUniversity Medical Center Utrecht · NLAarhus University · DKFederico II University Hospital · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITGerman Institute of Human Nutrition · DEGobierno del Principado de Asturias · ESHellenic Health Foundation · GRInstitut Català d'Oncologia · ESInstituto de Investigación Biosanitaria de Granada · ESInstituto Murciano de Investigación Biosanitaria · ESKarolinska Institutet · SENational and Kapodistrian University of Athens · GRNuffield Health · GBPrevention Institute · US
Funding
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MKIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIRR01DK072381 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2005 to 2025
$8.6MUrinary Biomarkers of Chronic Kidney Disease Pathology and ProgressionU01DK085660 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT, WAIKAR, SUSHRUT S. · 2009 to 2019
$5.3MMechanisms of Ischemic Kidney Injury and RepairR37DK039773 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 1993 to 2021
$5.2MCombating Resistance to Antiangiogenic Therapy in Renal Cell CarcinomaR01CA196996 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BHATT, RUPAL S · 2015 to 2019
$2.0MCancer Research UK 14136Cancer Research UK 16491Cancer Research UK 24390Cancer Research UK 25004Medical Research Council MR/M012190/1NCI NIH HHS P50 CA101942NCI NIH HHS R01 CA196996NIDDK NIH HHS R01 DK072381NIDDK NIH HHS R37 DK039773NIDDK NIH HHS U01 DK085660World Health Organization 001
Abstract
PubMed holds no abstract for this paper.
Indexed as
Biomarkers, TumorCarcinoma, Renal CellCase-Control StudiesEarly Detection of CancerFemaleFollow-Up StudiesHepatitis A Virus Cellular Receptor 1HumansKidney NeoplasmsMaleNeoplasm StagingPrognosisROC CurveBiomarkers, TumorHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.